Clinical trials: Negative Symptoms
Meningococcal Meningitis, Human Papillomavirus Infection
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents
This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine when administered with Tdap and HPV vaccinations to healthy adolescents
- Conditions
- Meningococcal Meningitis, Human Papillomavirus Infection, Pertussis, Tetanus
- Trial name
- NCT00518180
- Testing
- Novartis Meningococcal ACWY Conjugate Vaccine, Tdap Vaccine
- Where
- Costa Rica
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Castration Resistant Metastatic Prostate Cancer
Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance
Asymptomatic men with progressive metastatic Castration-resistant prostate cancer (CRPC) post- treatment with abiraterone acetate (pre-chemotherapy for metastatic disease) will be treated on a randomized, multi-Institutional open…
- Trial name
- Transformer (NCT02286921)
- Testing
- Testosterone cypionate, Enzalutamide, Testosterone Enanthate
- Where
- 17 sites in United States
- Volunteers
- 222 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, Metastatic Breast Cancer
Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer
This is a phase II single arm, open-label study of SM-88 used with methoxsalen, phenytoin, and sirolimus (MPS) in metastatic HR+/HER2- breast cancer.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma
- Trial name
- OASIS (NCT04720664)
- Testing
- SM-88
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Georgetown University
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00719849
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Fred Hutchinson Cancer Center
Clostridium Difficile Infection, Diarrhea
TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment
The purpose of this study is to determine the risks and benefits of antibiotic treatment for Clostridium difficile infection (CDI) among patients whose stool samples are nucleic acid amplification test (NAAT) positive and enzyme…
- Trial name
- NCT03388268
- Testing
- Oral Vancomycin, Toxin enzyme immunoassay, Nuceleic acid amplification test
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
Chronic Hepatitis B
Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B
A randomized, open-label multicentre clinical trial of daily Myrcludex B versus entecavir in patients with HBeAg negative chronic hepatitis B.
- Trial name
- NCT02881008
- Testing
- Entecavir, Myrcludex B
- Where
- 9 sites in Russia
- Volunteers
- 48 people
- Sponsor
- Hepatera Ltd.
Candidemia
Negative Beta Glucan in ICU Patients
This is a prospective study aimed at testing a strategy of early initiation of an antifungal agent to patients admitted to intensive care units (ICUs) at risk for invasive candidiasis.
- Trial name
- NCT01734525
- Testing
- Anidulafungin
- Where
- Brazil
- Volunteers
- 85 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Reproductive Tract Infections
Evaluation of Immediate v. Delayed CT/NG Test for Treatment in the ED
The purpose of this study is to determine if immediate availability of GeneXpert® CT/NG test results reduces the overtreatment rate for ED patients with suspected gonorrhea or chlamydia and to assess changes in clinician…
- Trial name
- NCT01989130
- Testing
- Roche AMPLICOR CT/NG, Cepheid Xpert CT/NG Test
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- George Washington University
Complications; Arthroplasty, Infection or Inflammation, Wound Complication
Improvement in Wound Healing With Negative Pressure Wound Therapy for Postoperative Total Hip Arthroplasty
For the target population of adult patients following primary total hip arthroplasty, the randomized clinical trial will be used to evaluate the efficacy of the use of a mobile negative pressure wound therapy(NPWT) device…
- Trial name
- NCT02355691
- Testing
- PREVENA
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of North Carolina, Chapel Hill
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
RATIONALE: Rasburicase may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying how well rasburicase works in preventing graft-versus-host…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00513474
- Testing
- busulfan, cyclophosphamide, cyclosporin-A
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Impact of Inflammation on Reward Circuits, Motivational Deficits and Negative Symptoms in Schizophrenia
This study will recruit persons with schizophrenia or schizoaffective disorder and will use an oral glucose tolerance test to test the hypothesis that insulin resistance drives inflammation.
- Trial name
- NCT03818516
- Testing
- Oral Glucose Tolerance Test (OGTT)
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- Emory University
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer
- Trial name
- NCT03829501
- Testing
- Alomfilimab, Atezolizumab
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 222 people
- Sponsor
- Kymab Limited
Metastatic Breast Cancer
Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
This international, multicenter, prospective single arm Phase II biomarker discovery clinical trial with the primary objective of assessing the association of PFS with gene mutations, gene copy number aberrations and gene…
- Trial name
- PYTHIA (NCT02536742)
- Testing
- Palbociclib, Fulvestrant
- Where
- 19 sites in Belgium, Italy and 1 more
- Volunteers
- 124 people
- Sponsor
- ETOP IBCSG Partners Foundation
Hepatitis B, Chronic
A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B
This single-arm study will evaluate the efficacy and safety of peginterferon alfa-2a in treatment-naive Baltic participants with Hepatitis B envelope antigen (HBeAg)-positive chronic Hepatitis B virus (HBV).
- Trial name
- NCT00436163
- Testing
- Peginterferon alfa-2a
- Where
- 9 sites in Estonia, Latvia and 1 more
- Volunteers
- 39 people
- Sponsor
- Hoffmann-La Roche
Surgical Site Infection
Prevena™ Incisional Negative Pressure Wound Therapy in Re-operative Colorectal Surgery
Many strategies have been attempted to reduce SSI rates. The Centers for Medicare and Medicaid Services introduced the Surgical Care Improvement Project infection project with the aim of reducing SSI incidence and morbidity.
- Trial name
- NCT02509260
- Testing
- Prevena wound management system, Standard wound dressings
- Where
- United States
- Volunteers
- 298 people
- Sponsor
- The Cleveland Clinic
Cancer
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, ondansetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients undergoing a stem cell transplant.
- Trial name
- NCT00248547
- Testing
- aprepitant, dexamethasone, ondansetron
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- OHSU Knight Cancer Institute
Hepatitis B, Chronic
A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
This study will compare the efficacy and safety of 2 different durations of treatment with pegylated interferon (PEG-IFN) alfa-2a in participants with Hepatitis B e Antigen (HBeAg)-negative chronic hepatitis B virus (HBV).
- Trial name
- NCT01095835
- Testing
- Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg, Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg, Lamivudine (LAM)
- Where
- 22 sites in Italy
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
This is an expanded access, multicenter, national, open-label, and non-randomized study to analyze the safety of peginterferon alfa-2a in participants with hepatitis B e antigen (HBeAg) positive and HBeAg negative chronic HBV…
- Trial name
- NCT02791269
- Testing
- Peginterferon alfa-2a
- Where
- 6 sites in New Zealand
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia and Predominant Negative Symptoms
Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms
To explore the efficacy of SPD489, as adjunctive therapy to a stable dose of atypical antipsychotic medication, on negative symptoms in adult subjects with clinically stable schizophrenia and predominant negative symptoms, as…
- Trial name
- NCT00922272
- Testing
- SPD489 (lisdexamfetamine dimesylate)
- Where
- 27 sites in United States
- Volunteers
- 92 people
- Sponsor
- Shire